LIS is a first-in-class anti-inflammatory drug – an inhibitor of inducible NO synthase (iNOS) enzyme. LIS inhibits iNOS, reducing the production of nitric oxide – the most important inducer of inflammation, pain and tissue damage.

Dosage form – hard gelatin capsules for oral administration. Original oral formulations have been developed that provide local action of LIS on intestinal tissues with minimal systemic bioavailability.

Injectable formulations are being developed, including intra-articular injections, which make it possible to achieve high concentrations of the active substance in the affected area at a minimum dose.

Patent profile: patented in Russia, EAEU, USA, EU.

Indications for use: With its novel mechanism of action, original formulations and unique efficacy and safety profile, LIS can be effective where other anti-inflammatory agents have little effect:

– ulcerative colitis and Crohn’s disease – virtually incurable inflammatory bowel diseases where LIS may become a first line drug, an alternative to mesalazine, immunosuppressants and glucocorticoids;

– infectious colitis – as part of complex therapy;

– colorectal cancer – the third most common cancer, with iNOS overexpression in the intestine, for which the efficacy of iNOS inhibitors in combination with targeted therapy is proven.

Main advantages:

High efficacy:

– in a model of ulcerative colitis LIS effectively (better than mesalazine – the “gold standard” of colitis therapy) reduces the severity of ulcerative mucosal lesions, the level and expression of iNOS, the level of pro-inflammatory cytokines IL-1, IL-6 and TNF-α;

– has not only anti-inflammatory but also anti-ulcer effect (unlike NSAIDs and glucocorticoids)

– in a model of rheumatoid arthritis effectively (at the level of the best NSAIDs) reduces pain, inflammation and restores tissue structure at the site of the lesion;

High safety:

– does not cause gastrointestinal mucosal damage, ulcers and bleeding (unlike NSAIDs);

– does not cause immunosuppression and, therefore, does not increase the risk of infections and cancer (unlike immunosuppressants);

– does not cause severe side effects, typical of glucocorticoids.

Current status: Substance and dosage forms (for oral and parenteral administration) are developed; samples for preclinical studies are produced at a licensed pilot production facility Preclinical studies of efficacy, safety and pharmacokinetics are ongoing.

Video: https://youtu.be/omtrXDryhU8